Dossier is the collaborative workspace for pharma market access. Generate AMCP-format payer dossiers, simulate P&T committee objections, and get answers in seconds instead of weeks — without a $400k consulting engagement.
Ingests clinical trials, RWE, and competitor labels. Outputs PICO-structured comparative effectiveness with traceable citations.
Drafts the AMCP 4.1 Global Value Dossier: unmet need, mechanism, clinical, economic, and patient value — quantified.
Role-plays national PBMs, BCBS, Medicare Part D, Medicaid MCOs, IDNs, and specialty carve-outs. Surfaces blockers before P&T does.
Disease landscaping across regulatory, HTA, and pricing intelligence to size the access opportunity.
Red-team the value story against PBMs, MCOs, Medicare, and IDNs before your real P&T review.
AMCP 4.1-formatted Global Value Dossier with citations, ready for analyst verification and MLR.
Emerging biotech can't wait three months and write a $400k check for a draft dossier. Dossier gets a Series B med affairs team to a payer-ready value story before the next leadership review.